153 related articles for article (PubMed ID: 12684001)
1. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors.
Zeslawska E; Jacob U; Schweinitz A; Coombs G; Bode W; Madison E
J Mol Biol; 2003 Apr; 328(1):109-18. PubMed ID: 12684001
[TBL] [Abstract][Full Text] [Related]
2. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
Katz BA; Mackman R; Luong C; Radika K; Martelli A; Sprengeler PA; Wang J; Chan H; Wong L
Chem Biol; 2000 Apr; 7(4):299-312. PubMed ID: 10779411
[TBL] [Abstract][Full Text] [Related]
4. (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
Sperl S; Jacob U; Arroyo de Prada N; Stürzebecher J; Wilhelm OG; Bode W; Magdolen V; Huber R; Moroder L
Proc Natl Acad Sci U S A; 2000 May; 97(10):5113-8. PubMed ID: 10805774
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
6. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).
West CW; Adler M; Arnaiz D; Chen D; Chu K; Gualtieri G; Ho E; Huwe C; Light D; Phillips G; Pulk R; Sukovich D; Whitlow M; Yuan S; Bryant J
Bioorg Med Chem Lett; 2009 Oct; 19(19):5712-5. PubMed ID: 19703768
[TBL] [Abstract][Full Text] [Related]
7. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
8. 4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.
Spencer JR; McGee D; Allen D; Katz BA; Luong C; Sendzik M; Squires N; Mackman RL
Bioorg Med Chem Lett; 2002 Aug; 12(15):2023-6. PubMed ID: 12113833
[TBL] [Abstract][Full Text] [Related]
9. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.
Hansen M; Wind T; Blouse GE; Christensen A; Petersen HH; Kjelgaard S; Mathiasen L; Holtet TL; Andreasen PA
J Biol Chem; 2005 Nov; 280(46):38424-37. PubMed ID: 16141208
[TBL] [Abstract][Full Text] [Related]
10. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents.
Schweinitz A; Steinmetzer T; Banke IJ; Arlt MJ; Stürzebecher A; Schuster O; Geissler A; Giersiefen H; Zeslawska E; Jacob U; Krüger A; Stürzebecher J
J Biol Chem; 2004 Aug; 279(32):33613-22. PubMed ID: 15150279
[TBL] [Abstract][Full Text] [Related]
11. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
12. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis.
Islam I; Yuan S; West CW; Adler M; Bothe U; Bryant J; Chang Z; Chu K; Emayan K; Gualtieri G; Ho E; Light D; Mallari C; Morser J; Phillips G; Schaefer C; Sukovich D; Whitlow M; Chen D; Buckman BO
Bioorg Med Chem Lett; 2018 Nov; 28(20):3372-3375. PubMed ID: 30201291
[TBL] [Abstract][Full Text] [Related]
13. 2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.
Mackman RL; Hui HC; Breitenbucher JG; Katz BA; Luong C; Martelli A; McGee D; Radika K; Sendzik M; Spencer JR; Sprengeler PA; Tario J; Verner E; Wang J
Bioorg Med Chem Lett; 2002 Aug; 12(15):2019-22. PubMed ID: 12113832
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of the protease domain of urokinase-type plasminogen activator.
Rockway TW; Nienaber V; Giranda VL
Curr Pharm Des; 2002; 8(28):2541-58. PubMed ID: 12369939
[TBL] [Abstract][Full Text] [Related]
15. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
Katz BA; Elrod K; Verner E; Mackman RL; Luong C; Shrader WD; Sendzik M; Spencer JR; Sprengeler PA; Kolesnikov A; Tai VW; Hui HC; Breitenbucher JG; Allen D; Janc JW
J Mol Biol; 2003 May; 329(1):93-120. PubMed ID: 12742021
[TBL] [Abstract][Full Text] [Related]
16. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.
Egelund R; Petersen TE; Andreasen PA
Eur J Biochem; 2001 Feb; 268(3):673-85. PubMed ID: 11168406
[TBL] [Abstract][Full Text] [Related]
17. A structural mechanism of flavonoids in inhibiting serine proteases.
Xue G; Gong L; Yuan C; Xu M; Wang X; Jiang L; Huang M
Food Funct; 2017 Jul; 8(7):2437-2443. PubMed ID: 28644504
[TBL] [Abstract][Full Text] [Related]
18. Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.
Mackman RL; Katz BA; Breitenbucher JG; Hui HC; Verner E; Luong C; Liu L; Sprengeler PA
J Med Chem; 2001 Nov; 44(23):3856-71. PubMed ID: 11689072
[TBL] [Abstract][Full Text] [Related]
19. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
[TBL] [Abstract][Full Text] [Related]
20. Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificity.
Sevillano N; Bohn MF; Zimanyi M; Chen Y; Petzold C; Gupta S; Ralston CY; Craik CS
Biochim Biophys Acta Proteins Proteom; 2021 Feb; 1869(2):140562. PubMed ID: 33221341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
